4 Week treatment for Injecting Drug Users with chronic hepatitis C A phase 4, post marketing randomized clinical open label trial comparing 4 weeks of Ledipasvir/Sofosbuvir (co-formulated) and Ribavirin against 4 weeks of Ledipasvir/Sofosbuvir (co-formulated), Ribavrin and Pegylated interferon alpha2a for injecting drug users with Chronic Hepatitis C and no liver impairment at a drug treatment center.
Phase of Trial: Phase IV
Latest Information Update: 23 Apr 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms 4 WIDUC
- 03 Mar 2017 Status changed from recruiting to completed.
- 09 Apr 2015 New trial record